Immunic Therapeutics

@ImmunicInc

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies

New York, NY
Vrijeme pridruživanja: siječanj 2018.

Tweetovi

Blokirali ste korisnika/cu @ImmunicInc

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ImmunicInc

  1. proslijedio/la je Tweet
    Poništi
  2. proslijedio/la je Tweet
    10. sij
    Poništi
  3. 10. sij

    The team is heading to for week these days. We are looking forward to an exciting, productive week and lively discussions with scientific, investor and BD experts.

    Poništi
  4. 10. sij

    Thank you, ! We wish you a healthy and successful year 2020, too!

    Poništi
  5. proslijedio/la je Tweet
    9. sij

    . exercises option to IMU-856 from ; financials undisclosed Modulator of transcriptional regulator of intestinal barrier function to start Ph1 in H1 2020

    Poništi
  6. proslijedio/la je Tweet
    8. sij

    In exchange for an upfront fee, Immunic picks up the exclusive rights to market IMU-856 in all countries.

    Poništi
  7. 8. sij

    Great start into the new year: Today, we exercised our option for the exclusive worldwide license to from ; phase 1 clinical studies to begin in the first half of 2020

    Poništi
  8. 1. sij

    Happy New Year 2020! May the new year bring joy, peace and happiness to you and your beloved ones!

    Poništi
  9. 20. pro 2019.

    Happy Holidays from the entire Immunic team! We wish you a relaxing and reflective holiday season and a peaceful start into the New Year 2020!

    Poništi
  10. 5. pro 2019.

    Our CFO, Sanjay Patel, will present a company overview at the @PiperJaffrayCo 31st Annual Healthcare Conference in today at 12:10 pm EST.

    Poništi
  11. proslijedio/la je Tweet
    4. pro 2019.

    Immunic, Inc. präsentiert auf der IBD Innovate Conference der Crohn's and Colitis Foundation erstmal...

    Poništi
  12. 4. pro 2019.

    Dr. Hella Kohlhof, our CSO, will present data on , for the first time, at today’s IBD Innovate conference, highlighting its potential to revolutionize the treatment of multiple diseases related to intestinal barrier function.

    Poništi
  13. 3. pro 2019.

    Our CSO, Dr. Hella Kohlhof, will present, for the first time, data on at the IBD Innovate Conference in tomorrow. The presentation will be part of the Small & Large Molecules session at 11:40 am EST.

    Poništi
  14. proslijedio/la je Tweet

    & are that can create physical & emotional challenges for patients. We asked the community what their biggest challenges are that they face while living with IBD. Here's what they had to say.

    Poništi
  15. proslijedio/la je Tweet
    20. stu 2019.

    Jefferies Healthcare Temperature Check: 80% of respondents expect to see M&A increase or stay at same level in 2020

    Poništi
  16. proslijedio/la je Tweet
    25. stu 2019.

    Immunic, Inc. kündigt Teilnahme an Investorenkonferenzen und wissenschaftlichen Kongressen im Dezemb...

    Poništi
  17. 25. stu 2019.

    Immunic, Inc. to Participate in Investor and Scientific Conferences in December: 31st Annual Conference, Crohn's and Colitis Foundation Innovate Conference: @PiperJaffrayCo

    Poništi
  18. proslijedio/la je Tweet
    19. stu 2019.

    Immunic, Inc. erweitert Board of Directors mit der Ernennung des Biotechnologie-Experten Barclay A. ...

    Poništi
  19. 20. stu 2019.

    Our CFO, Sanjay Patel, and our IR & Comms Manager, Jessica Breu, are attending 2019 Conference in today and tomorrow and are looking forward to hosting 1x1 meetings.

    Poništi
  20. 19. stu 2019.

    We are very proud to announce the appointment of Barclay A. Phillips, an established executive, investor and entrepreneur, to our Board of Directors, effective November 14, 2019. Welcome to the team, Buck!

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·